| 临床特点 | ABL激酶突变率(%) | P值(χ2) | ||
| 突变 | 未突变 | |||
| 性别 | 男 | 7 (17.07) | 34 (82.93) | 0.735 |
| 女 | 8 (20.00) | 32 (80.00) | ||
| 年龄(岁) | <45 | 10 (26.32) | 28 (73.68) | 0.032 |
| ≥45 | 5 (11.63) | 38 (88.37) | ||
| 白细胞计数(×10^9/L) | <30 | 5 (12.20) | 36 (87.80) | 0.138 |
| ≥30 | 10 (25.00) | 30 (75.00) | ||
| 血红蛋白(g/L) | <89 g/L | 9 (22.50) | 31 (77.50) | 0.362 |
| ≥89 g/L | 6 (14.63) | 35 (85.37) | ||
| 血小板(×10^9/L) | <47 | 10 (25.64) | 29 (74.36) | 0.112 |
| ≥47 | 5 (11.90) | 37 (88.10) | ||
| 骨髓原始及幼稚细胞(%) | <82 | 8 (19.51) | 33 (80.49) | 0.816 |
| ≥82 | 7 (17.50) | 33 (82.50) | ||
| FAB分型 | L1 | 5 (20.83) | 19 (79.17) | 0.682 |
| L2 | 9 (19.57) | 37 (80.43) | ||
| 未分型 | 1 (9.10) | 10 (90.91) | ||
| 免疫学分型 | Com-B | 12 (18.46) | 53 (81.54) | 0.891 |
| Pre-B | 3 (20.00) | 12 (80.00) | ||
| T |
| 1 | ||
| 染色体核型 | Ph+ | 14 (22.58) | 48 (77.42) | 0.173 |
| Ph+合并其他 | 1 (5.26) | 18 (94.74) | ||
| BCR/ABL | P190 | 10 (29.41) | 24 (70.59) | 0.036 |
| P210 | 5 (10.87) | 41 (89.13) | ||
| P190+210 |
| 1 | ||
| 诱导化疗方案 | 传统化疗 | 4 (10.26) | 34 (89.74) | 0.074 |
| 传统化疗+TKIs | 12 (28.57) | 30 (71.43) | ||
| TKIs | 伊马替尼 | 10 (18.52) | 44 (81.48) | 0.744 |
| 达沙替尼 | 5 (21.74) | 18 (78.26) | ||